| Nov 12 |
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
|
| Nov 7 |
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
|
| Nov 6 |
Surmodics Non-GAAP EPS of -$0.13 beats by $0.16, revenue of $33.2M beats by $2.8M
|
| Nov 6 |
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
|
| Nov 6 |
SurModics: Fiscal Q4 Earnings Snapshot
|
| Nov 6 |
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
|
| Oct 30 |
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
|
| Oct 2 |
SRDX Stock Down Despite FDA Clearance for Pounce XL System
|
| Oct 1 |
Surmodics receives FDA clearance for its thrombectomy system
|
| Oct 1 |
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
|
